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SUMMARY
The increased knowledge regarding proteomic analysis techniques has allowed for better 
understanding of the molecular bases related to the identification of cell signaling, modi-
fying protein, and post-translational modification pathways, in addition to the charac-
terization of specific biological markers. Thus, documenting certain proteins expressed 
in sepsis is a promising approach to elucidate pathophysiological, diagnostic, therapeu-
tic, and prognostic aspects in this condition with a purpose of applying them to clinical 
practice. Although the studies are still preliminary, proteomics may offer good benefits 
for the better management of septic patients. Thus, this article aims to introduce a short 
review of the applications of proteomic studies to sepsis.
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INTRODUCTION
Sepsis – a systemic inflammatory response syndrome (SIRS) 
triggered by infection (supposed or confirmed) – is an ex-
tremely important condition from a clinical care and public 
health perspective1. It is one of the most important infec-
tious complications in contemporary medicine both for its 
incidence and severity, as well as for its great potential of 
progression to death (high lethality, depending on the stage 
presented when diagnosed)2-5.
The different possibilities of interaction between Homo 
sapiens sapiens and different etiological agents6 make differ-
ent clinical manifestations possible, making it important to 
distinguish situations such as infection, SIRS, sepsis, severe 
sepsis, septic shock, and multisystem organ dysfunction 
(MSOD)7,8.
In addition to the scientific issue – comparability across 
case studies – the terminological definition has aimed at 
early bedside detection. In this domain, instituting appro-
priate strategies to approach the patient could lead to a 
more favorable outcome and consequent reduced mortality. 
Diagnostic and therapeutic breakthroughs are the focus of 
scientific investigation, leading to an expansion of knowl-
edge in the field, and stressing the recent role that proteomic 
techniques (identification of all proteins encoded by the ge-
nome9) have gained in the study of sepsis in terms of patho-
physiology, diagnosis, therapeutics, and prognosis. To that 
effect, this article introduces a short review of the applica-
tions of proteomic studies in sepsis, considering their future 
incorporation into clinical practice.
METHODS
The article was elaborated from a literature review with a def-
inite search strategy. The articles were searched for in the U.S. 
National Library of Medicine (PubMed) and in the Scientific 
Electronic Library Online (SciELO), comprising the period 
from January 1, 2000 to September 1, 2011, with only studies 
performed in humans being selected. The terms used were:
Strategy 1 – sepsis + proteomics
Strategy 2 – sepsis + proteome
Strategy 3 – sepsis + proteomics + diagnosis
Strategy 4 – sepsis + proteomics + treatment
Strategy 5 – sepsis + proteomics + outcome
Strategy 6 – sepsis + proteomics + prognostic
In addition to articles, textbooks on internal medicine, 
infectology, and critical care were consulted as part of the 
bibliographical survey. The search retrieved the citations 
distributed according to Table 1. Out of the total articles 
retrieved, 25 were selected – resulting from empirical in-
vestigations and literature reviews –, mainly focusing on 
sepsis proteomic study and pathophysiological and clinical-
therapeutic aspects, which formed the basis of the current 
investigation.
The articles were read and information was orga-
nized into different sections: (1) proteome concept; (2) 
proteome and sepsis pathophysiology; (3) proteome 
and sepsis diagnosis; (4) proteome and sepsis treatment; 
(5) proteome and sepsis prognosis; and (6) concluding 
comments.
THE PROTEOME CONCEPT
The proteome reflects the functional expression of the ge-
nome, that is, the current functioning status of a certain 
biological system in specific physiological conditions. 
This characteristic makes the study of the proteome an 
important challenge, as cell gene expression is quite dy-
namic, depending on the development status, the pres-
ence of activators or inhibitors and the environment 
conditions. Despite this, proteomics is now considered 
the most appropriate tool to understand gene function-
ing, as it analyzes the genome’s end product9. Although 
identifying all of the proteins encoded into an organism 
genome appears to be a very difficult task, even in sim-
pler organisms, the information from proteomic studies 
is increasingly complete10. These new findings are related 
to cell signaling pathways, regulatory protein sets, post-
translational modifications as well as cell and organism 
states in health or sickness11.
Since Wasinger et al.12 proposed the proteome con-
cept in 1995, investigations through proteomic analysis – 
involving systematic screening of great numbers of pep-
tides contained in the cells, tissues, and biological fluids 
(e.g., cerebrospinal fluid, blood, urine, pancreatic fluid, 
amniotic fluid) – have rapidly advanced, characterizing 
the research field termed proteomics. These studies may 
lead to three basic aspects directly implicated in vari-
ous biology, biotechnology and medical science fields: 
(1) the discovery of metabolic pathways in various cell 
steps, generating unprecedented knowledge in molecular 
biology and biochemistry; (2) identification of new bio-
active molecules in natural biological extracts, leading 
to the development of new drugs; and (3) characteriza-
tion of biological markers, that is, specific endogenous 
and exogenous molecules in a determined nosological 
entity. The ability to identify these molecules can become 
exceedingly useful in the early diagnosis of diseases and 
in the follow-up of treatment progress11. Currently, the 
main techniques used in proteomics are two-dimension-
al (2D) electrophoresis and mass spectrometry.
Proteomic analysis can be seen as a peptide screening 
aiming to document the overall distribution of peptides 
in cells, tissues, organs, and other specimens by identi-
fying and characterizing individual proteins of interest 
and finally elucidating their interactions and roles in 
cell biology, in physiological and pathological contexts. 
Compared with the genome microarray technique, the 
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Search strategy
Database consulted
PubMed* SciELO
Stragegy 1 (sepsis + proteomics) 69 1
Strategy 2 (sepsis + proteome) 40 0
Strategy 3 (sepsis + proteomics + diagnosis) 34 0
Strategy 4 (sepsis + proteomics + treatment) 26 0
Strategy 5 (sepsis + proteomics + outcome) 5 0
Strategy 6 (sepsis + proteomics + prognostic) 0 0
*To search PubMed database by employing English words, the following limits were used: articles on adult (> 19 years) humans published 
between January 1, 2000 and September 1, 2011.
Table 1 – Number of articles obtained from the bibliographic survey
proteomic approach has the advantage of detecting pep-
tides previously, while microarrays only allow for the 
measurement of already defined genes. In parallel with 
proteomic advances, efforts to apply proteomic analysis 
to discover new biomarkers for pathophysiology descrip-
tion have been reported for a wide range of diseases, in-
cluding sepsis.  This point will be further discussed.
THE PROTEOME IN SEPSIS PATHOPHYSIOLOGY
The pathophysiology of sepsis depends on the relationships 
established between the etiological agent and the host8,13,14. 
Many aspects concerning the triggering of this morbid con-
dition are still unclear, likely because there is not a more 
appropriate understanding of the immune response bio-
chemical aspects and of the inflammatory process6. Some 
hypotheses to explain sepsis genesis have been proposed, be-
ing considered in terms of (1) pathogen/innate immune sys-
tem, (2) immune and adaptive inflammation/mediation, and 
(3) coagulation system, as discussed in a previous research8.
The interaction between the microbial agent and the 
host is initiated by recognizing not-self substances (the 
host’s non-particular substances) from the microorgan-
ism, the pathogen-associated molecular patterns (PAMPs) 
– non-variable molecules expressed by groups of etiologic 
agents, which are usually crucial for the microorganism’s 
virulence and/or survival – identified by the pattern rec-
ognition receptors (PRRs), which are cell structures en-
coded by the germlines and expressed by innate immune 
system cells15. The most potent and best-studied PAMPs 
are the endotoxins of Gram-negative bacteria, derived 
from their cell walls and mainly formed by lipopolysac-
charides (LPS). Regarding PRRs, the significant Toll-like 
family, whose molecules are identified in the surface of 
monocytes, macrophages, dendritic cells, and neutrophils, 
should be highlighted16. Polymorphisms in these receptors 
seem to decisively implicate in the possibility – or not – of 
a progression into severe sepsis and septic shock17. Con-
tinuing the recognition phase, various cell activation and 
cytokine production events succeed, resulting in SIRS.
Following the binding between PAMPs and Toll-like 
receptors, there is an intracellular domain activation in 
the latter, culminating in the activation of MyD88 pro-
tein (myeloid differentiation protein)18. The interaction 
of MyD88 with the IRAK (interleukin-1 receptor-asso-
ciated kinase, a serine-threonine kinase) enzyme leads 
to the activation of kinases IkKa and IkKB, which form 
the KkK dimer, which, in turn, “disconnects” the protein 
IkB (NF-kB inhibitor), linked to the nuclear transcrip-
tion factor NF-kB (nuclear factor kB), responsible for the 
activation of transcription genes in numerous cytokines 
which are part of SIRS (whether or not they are associ-
ated with infection)19,20.
The intracellular events described, especially NF-
kB release, determine the production and secretion of 
many proinflammatory cytokines, such as interleukins 1 
(IL-1), 2 (IL-2), 6 (IL-6), 8 (IL-8), 12 (IL-12), tumor ne-
crosis factor-alpha (TNF-α) and tumor necrosis factor-
beta (TNF-β); this event is considered crucial to sepsis 
development. Of note, a number of patients progress to 
early death resulting from severe systemic inflammatory 
response. Nevertheless, anti-inflammatory cytokines, 
such as interleukins 4 (IL-4), 5 (IL-5), 10 (IL-10), 11 
(IL-11), and 13 (IL-13) are equally produced – especially 
in settings wherein the patient survives systemic inflam-
mation-associated disorders – making the development 
of anergy possible and slowing of the response to etio-
logic agents in a typical immunosuppression context5, 
which, in sepsis, is differently named: immunoparalysis, 
immunodeficiency window, or compensatory anti-in-
flammatory response syndrome (CARS)21. This pro/an-
ti-inflammatory balance regulation is complex, and the 
role of monocytes/macrophages as adaptive immune re-
sponse activators must be emphasized. As macrophages 
phagocytize necrotic cells or bacteria, they induce Th1 
lymphocyte phenotype, leading to the release of proin-
flammatory substances, such as alpha-interferon (a-IFN), 
delta-interferon (d-IFN), and IL-2; if they phagocytize 
apoptotic cells, Th2 lymphocyte phenotype is activated, 
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leading to IL-4 and IL-10 production, which “brakes” the 
proinflammatory response22. Indeed, apoptosis is one of 
the significant events triggering immunosuppressor pro-
cesses23. The balance between proinflammatory and anti-
inflammatory mediators is increasingly recognized as the 
key to explain the morbid condition progression either to 
resolution or death8, as they can lead to a deep “immu-
nological dissonance” termed mixed antagonist response 
syndrome (MARS), wherein both SIRS and CARS are si-
multaneously found in the same patient24.
Proteomic studies have added important elements 
to the understanding of this complex “physiopathogenic 
web”. In a pilot study performed by Paiva et al.25 in order 
to better understand sepsis molecular bases, the differ-
ential expression of serum proteins in septic patients in 
different severity stages (sepsis, severe sepsis, and septic 
shock) were identified and analyzed through proteomic 
techniques. Fourteen differentially expressed proteins 
were identified across sepsis stages, as well as a protein not 
expressed in all stages, suggesting the possibility of the ex-
istence of a biomarker. The proteins were: serum amyloid 
A, apolipoprotein A-1 (two isoforms), zinc finger protein 
222, human albumin, PRO 2619, immunoglobulin kappa 
light chain VLJ region, monoclonal immunoglobulin M 
with cold agglutinin activity, and seven alpha-1 antitrypsin 
protease inhibitors25. The results achieved from this pilot 
study demonstrated the participation of the complement 
and coagulation pathways of the lipid metabolism and of 
the genetic information in sepsis. The majority of peptides 
identified are involved in the immune system, and prote-
ase inhibitor peptides predominate25.
PROTEOME AND SEPSIS DIAGNOSIS
Despite the extensive knowledge production regarding 
pathophysiology and treatment, sepsis remains a dif-
ficult entity for clinical management2,26. Several studies 
have suggested the presence of specific genetic polymor-
phisms during sepsis27. Other investigations have used a 
microarray technology to compare gene expression levels 
after the administration of endotoxin28. However, gene 
expression studies cannot accurately predict the struc-
ture or the dynamics of the respective characteristic pro-
teins in sepsis. RNA patterns do not appropriately reflect 
the proteomic pattern – that is, proteins expressed –, as 
in the analysis of many proteomic patterns of regulatory 
processes, such as post-translational modifications29.
A great number of biological substances have been 
investigated as biochemical mediators and/or candidate 
biomarkers for sepsis laboratory investigation. C-reactive 
protein (CRP)30, procalcitonin30,31, and IL-6 are consid-
ered useful in the diagnosis and in the severity rating of 
sepsis, despite some limitations. More recently, attempts 
to show clinical usefulness as sepsis biomarkers were 
documented for a wide range of molecules, including the 
high mobility group box 1 protein (HBGB-1) and the trig-
gering receptors expressed on myeloid cells (TREM-1)8. 
Some sepsis biomarkers, such as the cytokines, are also 
considered important disease mediators, so that the 
modulation of these substances may have therapeutic 
importance32. In addition, the combined use of multiple 
molecular markers or the use of more accurate prognosis 
scores for the severity allows for rating and predicting the 
sepsis outcome8. Finding new mediators involved in sep-
sis physiopathology, as well as new biomarkers allowing 
a more accurate sepsis diagnosis and prognosis is, thus, 
urgently needed.
Proteomic analysis methods can be used to investi-
gate protein profiles in patients with sepsis and septic 
shock, thus revealing differences in protein electrophore-
sis mapping among patients who survive and those pro-
gressing to death. These studies indicate two important 
results. First, proteomic analysis can become a feasible 
tool to exclude early changes in peptide expression in pa-
tients with septic shock. Second, there are specific pro-
tein changes among survivors and non-survivors on day 
28 in an initial stage of septic shock. This can be found 
in samples obtained over the first 12 hours after septic 
shock diagnosis.
Early sepsis diagnosis based only on clinical elements 
is known to be very difficult, although it is an essential 
aspect to approach patients, allowing the immediate ini-
tiation of an appropriate antibiotic therapy, which could 
greatly impact the patients’ survival33. Paugam-Burtz et 
al.34, by using a proteomic approach termed surface en-
hanced laser desorption/ionization – time-of-flight mass 
spectrometry (SELDI-TOF MS) for patients’ serum  eval-
uation within five days of liver transplantation, obtained 
a profile containing five peptides identifying sepsis. The 
comparison of protein profiles obtained in the sepsis group 
(n = 31) showed a total of 29 differentially expressed pro-
tein peaks, compared with the non-septic group (n = 30). 
Fourteen peptides profiles had their expression enhanced 
in the septic group, whereas 15 were restrained. As this is 
a preliminary study, the proteins are still being identified 
by those authors34.
PROTEOME AND SEPSIS TREATMENT
The literature search proceeded with the terms sepsis + 
prognosis + proteomics not resulted in obtaining of cita-
tions in two databases consulted. However, information 
was gathered from articles selected for review.
Most proteomic studies involving sepsis focus on the 
disease physiopathology and on the detection of proteins 
that could serve as diagnostic biomarkers, proposing com-
parisons between sera from both septic and non-septic 
patients, and comparison across proteomic data from 
RODRIGO SIQUEIRA-BATISTA ET AL.
380 Rev Assoc Med Bras 2012; 58(3):376-382
patients with sepsis, severe sepsis, and septic shock, to 
identify protides specifically expressed either in this mor-
bid condition or in one of its stages. Studies on sepsis treat-
ment using proteomic technology are still rare.
Techniques of continuous renal replacement therapy 
(CRRT) have been occupying an important position in 
intensive care units (ICUs), employed in severe sepsis 
treatment when acute renal failure has already super-
vened7,35. Many water-soluble proteins with pro and anti-
inflammatory activity play important roles in the severe 
sepsis pathophysiological process and are inflamma-
tory response mediators. The clearance of these soluble 
proteins may account for a number of CRRT beneficial 
effects36. Changes occurring in serum proteome of pa-
tients undergoing CRRT remain unclear. As there is not 
a perfect understanding of CRRT, and there is no spe-
cific biomarker describing treatment progress,  Gong et 
al.37 investigated the proteome changes in patients with 
severe sepsis on CRRT. Ten proteins were identified as 
differentially expressed during CRRT. They include syn-
taxin-1B1 (an antithrombin III variant), CD5 antigen-
like precursor, apolipoprotein A-IV precursor, apolipo-
protein B-100 precursor, gamma-A isoform of fibrinogen 
gamma chain precursor, isoform 2 of ubiquitin E1-like 
activation enzyme, 36-kDa protein, MYH2 protein, and 
SPTAN1 protein (fragment). Among them, seven pro-
teins were reduced in serum and three were increased 
during CRRT37. Western blot was performed to validate 
the study, evidencing the expression of CD5 antigen-like 
precursor and gamma-A isoform of fibrinogen gamma 
chain precursor in serum samples obtained from both 
patients on CRRT and controls (septic patients with no 
organ dysfunction and not treated by CRRT). The inves-
tigators detected both proteins in the serum of patients 
on CRRT but not in control patients37.
CD5 antigen-like precursor was reduced in serum 
during CRRT. This protein: (1) plays an important role in 
regulating innate and adaptive immune systems38, (2) in-
duces aggregation of Gram-positive and Gram-negative 
bacteria, and (3) inhibits TNF-a secretion, a mediator 
playing a pivotal role in severe sepsis. Many of the in-
nate immune response components normally involved 
in the Homo sapiens sapiens response to infection may 
occasionally damage cells and tissues, leading to multi-
system organ failure39. CD5 antigen-like precursor was 
significantly high in patients’ serum before CRRT and 
was reduced on CRRT37.
An increase in gamma-A isoform of the fibrinogen 
gamma chain precursor in serum was observed during 
CRRT. Fibrinogen is a part of homeostasis events, being 
an acute phase reactant that responds to stress40. Differ-
ent cells can produce cytokines, inducing an acute phase 
reaction and therefore increasing fibrinogen plasma 
levels41. The increased detection of serum gamma-A iso-
form of fibrinogen gamma chain precursor during CRRT 
suggests that the patients’ immune system functioning 
has been partially restored37.
By using differential gel electrophoresis (DIGE) – a 
proteomic technique in 2D gel using up to three differ-
ent protide samples labeled by fluorescent dyes – Holly et 
al.35 identified changes in the number of rat urinary pro-
teins, including albumin, kidney brush-border enzymes 
(e.g., meprin-1-alpha), and serine protease inhibitors. 
Meprin is a brush-border enzyme playing a role in inju-
ries related to ischemia and renal reperfusion. Meprin in-
hibition prevents in vitro hypoxic injury and in vivo isch-
emia/reperfusion injury42. This enzyme increase reflects 
kidney brush-border loss following sepsis-induced acute 
renal failure (chiefly septic shock). Treatment with acti-
nonin, a meprin inhibitor, prevented acute renal failures 
in animal experiments35. This demonstrates the potential 
use of meprin as a sepsis biomarker and drug target in 
sepsis treatment.
PROTEOME AND SEPSIS PROGNOSIS
In the prognosis evaluation of a patient with sepsis, the 
acute physiologic chronic health evaluation (APACHE 
II) score can be used, although the best strategy for 
this purpose is the sequential organ failure assessment 
(SOFA) score, which comprises respiratory, hematologi-
cal, hepatic, cardiovascular, neurological, and renal vari-
ables43. The multiple organ dysfunction score (MODS) is 
also available, selecting six organ systems (respiratory, 
renal, hepatic, cardiovascular, hematological, and neuro-
logical) and easily scoring each observed dysfunction, al-
lowing for an objective measurement of organic dysfunc-
tion severity at admission and follow-up by evaluating 
the dysfunction throughout hospitalization44. Recently, 
the association of inflammation biomarkers with these 
scores is considered to enhance the prognostic evalua-
tion in patients with sepsis45.
Another important reference to assess patients with 
sepsis is the PIRO concept, which is substantiated on 
multivariate elements, including predisposing condi-
tions, insult quality and range, type and magnitude of 
the host response (deleterious response), and resulting 
or preexisting organic dysfunction (organic failure)46. 
The PIRO concept is interesting to rate septic patients, 
aiming at the development of studies to understand the 
physiopathology and improve therapeutics47.
In addition to searching for biomarkers to identify 
sepsis and its variations, investigators seek markers to 
determine the disease prognosis by trying to identify the 
disease course and appropriate treatment on the basis 
of immune information and the patient’s inflammatory 
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status. This information can be studied through pro-
teomics technology, which, along with APACHE II, 
SOFA, and PIRO, will allow advances in sepsis treatment, 
prognosis, and outcome.
Sepsis prognosis studies using the above concepts and 
molecular studies,  such as proteomics, are few31,32,48. In 
this field, recent investigation has revealed that, in early 
sepsis, there are significant differences in protein expres-
sion in patients surviving the condition versus those who 
do not. Patients surviving sepsis exhibited a strong ac-
tivation of proteins involved in antibody-independent 
monocyte-mediated cytotoxicity, macrophage spread, 
plasminogen activation, and B lymphocyte prolifera-
tion. Survivors are thought to have a more efficient im-
mune response. A study in 124 sepsis patients – with and 
without septic shock – was conducted by Oberholzer et 
al.32 and evaluated not only the APACHE II and MODS 
scores, but also the proinflammatory and anti-inflamma-
tory cytokine concentrations, as well as the procalcitonin 
and CRP levels. Correlations of these parameters with 
protein levels were established, and protein plasma con-
centrations of all cytokines and humoral mediators were 
high. IL-6 and sTNFR I concentrations, were significantly 
higher in patients surviving after 28 days, but not TNF-a, 
IL-8, IL-10, procalcitonin, and CRP concentrations. IL-6 
concentration alone or in combination with APACHE-II 
or MODS scores is a strong candidate to predict clinical 
outcome in patients with severe sepsis32.
CONCLUSION
Sepsis, despite being a very frequent condition in clini-
cal practice, still remains enigmatic from different points 
of view. Indeed, there are very unclear points regarding 
physiopathology, diagnostic accuracy, therapy, and prog-
nosis – which are related to the lack of information about 
many immune system aspects –, for which new investiga-
tions can bring light to in the near future.
In this field, proteomic studies stand out – being 
employed to understand different infectious conditions 
– and although the results are still quite preliminary in 
investigating sepsis, they have already shown great po-
tential to become useful tools in the patient manage-
ment, thus contributing to the much needed full care of 
patient.
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